) The scientific goals of the Cell Biology Program are 1)to understand the mechanisms of cell proliferation and cell death and of cancer development, progression, invasion and metastasis, and 2)to develop cancer intervention strategies based on this understanding. The Program endeavors to enhance infrastructure support for this research by providing seminars, core support and mentoring, by conducting recruitments, and by facilitating research collaborations. The Cell Biology Program's unifying research theme comprises the regulatory mechanisms involved in proliferation and apoptosis, membrane traffic and receptor recycling, cell surface interactions and motility, and their applications to cancer. There are three partially overlapping focus areas: """"""""Proliferation and Apoptosis,"""""""" """"""""Host-Tumor Interactions,"""""""" and """"""""Membrane Traffic."""""""" The Program includes an outstanding signaling group with two HHMI investigators and a Jimmy V awardee, and it has generated numerous intra- and inter-program collaborations and several jointly held research grants. The 29 members of the Program have about $7.5 million in annual direct cost grant support. This includes 14 projects funded by the NCI and other cancer (peer-reviewed) agencies totaling over $900,000 in annual direct support, as well as several program project and other multi-member grants. The Program's activities include the establishment of a new seminar series, the organization of interdisciplinary basic-clinical minisymposia, the granting of pilot and postdoctoral development awards, the participation in core development (protein analysis, mass spectrometry, and cell imaging), and the recruitment of a new faculty member in the area of cell adhesion/motility/metastasis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA046934-14
Application #
6488471
Study Section
Subcommittee E - Prevention &Control (NCI)
Project Start
1988-03-01
Project End
2006-01-31
Budget Start
Budget End
Support Year
14
Fiscal Year
2001
Total Cost
Indirect Cost
Name
University of Colorado Denver
Department
Type
DUNS #
065391526
City
Aurora
State
CO
Country
United States
Zip Code
80045
Tuttle, Kathryn D; Krovi, S Harsha; Zhang, Jingjing et al. (2018) TCR signal strength controls thymic differentiation of iNKT cell subsets. Nat Commun 9:2650
Keysar, Stephen B; Eagles, Justin R; Miller, Bettina et al. (2018) Salivary Gland Cancer Patient-Derived Xenografts Enable Characterization of Cancer Stem Cells and New Gene Events Associated with Tumor Progression. Clin Cancer Res 24:2935-2943
Salmon, Loïc; Stull, Frederick; Sayle, Sabrina et al. (2018) The Mechanism of HdeA Unfolding and Chaperone Activation. J Mol Biol 430:33-40
Kleczko, Emily K; Heasley, Lynn E (2018) Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities. Mol Cancer 17:60
Steckelberg, Anna-Lena; Akiyama, Benjamin M; Costantino, David A et al. (2018) A folded viral noncoding RNA blocks host cell exoribonucleases through a conformationally dynamic RNA structure. Proc Natl Acad Sci U S A 115:6404-6409
Pilling, Amanda B; Kim, Jihye; Estrada-Bernal, Adriana et al. (2018) ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer. Oncotarget 9:8823-8835
Antonioli, Alexandra H; White, Janice; Crawford, Frances et al. (2018) Modulation of the Alternative Pathway of Complement by Murine Factor H-Related Proteins. J Immunol 200:316-326
Boswell, Zachary K; Rahman, Samiur; Canny, Marella D et al. (2018) A dynamic allosteric pathway underlies Rad50 ABC ATPase function in DNA repair. Sci Rep 8:1639
Fitzwalter, Brent E; Towers, Christina G; Sullivan, Kelly D et al. (2018) Autophagy Inhibition Mediates Apoptosis Sensitization in Cancer Therapy by Relieving FOXO3a Turnover. Dev Cell 44:555-565.e3
Duex, Jason E; Swain, Kalin E; Dancik, Garrett M et al. (2018) Functional Impact of Chromatin Remodeling Gene Mutations and Predictive Signature for Therapeutic Response in Bladder Cancer. Mol Cancer Res 16:69-77

Showing the most recent 10 out of 1634 publications